2,6-Dimethoxyamphetamine

Pharmaceutical compound From Wikipedia, the free encyclopedia

2,6-Dimethoxyamphetamine (2,6-DMA), also known as DMA-5, is a drug of the phenethylamine and amphetamine families.[1] It is one of the positional isomers of dimethoxyamphetamine.[1]

Other names2,6-DMA; DMA-5
ATC code
  • None
Quick facts Clinical data, Other names ...
2,6-Dimethoxyamphetamine
Clinical data
Other names2,6-DMA; DMA-5
Drug classSerotonin receptor modulator
ATC code
  • None
Identifiers
  • 1-(2,6-dimethoxyphenyl)propan-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC11H17NO2
Molar mass195.262 g·mol−1
3D model (JSmol)
  • CC(CC1=C(C=CC=C1OC)OC)N
  • InChI=1S/C11H17NO2/c1-8(12)7-9-10(13-2)5-4-6-11(9)14-3/h4-6,8H,7,12H2,1-3H3
  • Key:OHGNLLDQBKOWJW-UHFFFAOYSA-N
Close

The drug has not been tested in humans and its effects in humans are unknown.[1]

2,6-DMA showed very low affinity for serotonin receptors in rat stomach fundus strips (A2 = 8,130 nM).[1][2] In a subsequent study, it showed no affinity for the serotonin 5-HT2A or 5-HT2C receptors (Ki = >10,000 nM).[3] 2,6-DMA only partially substituted for DOM in rodent drug discrimination tests, with a maximum responding of 41% and behavioral disruption at higher doses.[4][5] It did not substitute for dextroamphetamine in these tests.[5][6]

The chemical synthesis of 2,6-DMA has been described.[1]

2,6-DMA was first described in the scientific literature by Alexander Shulgin by 1969.[7] At that time, he had not yet synthesized it and did not report its effects.[7] 2,6-DMA is a positional isomer of 2,5-dimethoxyamphetamine (2,5-DMA) and hence is a Schedule I controlled substance in the United States.[1]

See also

References

Related Articles

Wikiwand AI